H-Pharm's Propin capsule designated as first bioequivalence test-waivered item
Published: 2002-08-14 06:57:00
Updated: 2002-08-14 06:57:00
The Korea Food and Drug Administration (KFDA) announced that H-Pharm's antidepressant Propin capsule (fluoxetine HCl) was granted as the first bioequivalence test-waivered item, since its policy of expanding the waiver scope of bioequivalence test on June 20 this year.
A KFDA official said tha...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
